Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Mar 26, 2023

Press releases

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy

This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy

Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)

Mar 15, 2023

Press releases

Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)

COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.

Evaxion and Pantherna announce promising preclinical mRNA vaccine data

Feb 8, 2023

Press releases

Evaxion and Pantherna announce promising preclinical mRNA vaccine data

Evaxion and Pantherna announced that the tumor neoantigens, identified by Evaxion's PIONEER, demonstrates strong immune response

Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

Jan 3, 2023

Press releases

Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

Evaxion today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

Dec 15, 2022

Press releases

Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

Evaxion today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.

Evaxion and ExpreS<sup>2</sup>ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

Dec 6, 2022

Press releases

Evaxion and ExpreS2ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

Evaxion has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech for the joint development of a novel cytomegalovirus (CMV) vaccine candidate

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Nov 17, 2022

Press releases

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Evaxion announced today promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

Nov 14, 2022

Press releases

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

Evaxion announced today its third quarter 2022 financial results and provided an operational and business update

Evaxion CEO comments on strategic focus

Nov 10, 2022

Press releases

Evaxion CEO comments on strategic focus

Evaxion today announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by out-licensing. The Company further plans preclinical partnering of its early-stage programs under its infectious disease platforms.